Ads
related to: ghrhr receptor therapy for prostate cancer
Search results
Results from the WOW.Com Content Network
Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...
Flutamide (Eulexin): Marketed for the treatment of prostate cancer and also used in the treatment of acne, hirsutism, and hyperandrogenism in women. [3] [4] It has also been studied in the treatment of benign prostatic hyperplasia. [6] Now little-used due to high incidence of elevated liver enzymes and hepatotoxicity and the availability of ...
The reduction in testosterone levels that occurs during GnRH antagonist therapy subsequently reduces the size of the prostate cancer. This in turn results in a reduction in prostate-specific antigen (PSA) levels in the patient's blood and so measuring PSA levels is a way to monitor how patients with prostate cancer are responding to treatment ...
Flutamide, sold under the brand name Eulexin among others, is a nonsteroidal antiandrogen (NSAA) which is used primarily to treat prostate cancer. [9] [10] It is also used in the treatment of androgen-dependent conditions like acne, excessive hair growth, and high androgen levels in women. [11] It is taken by mouth, usually three times per day ...
14602 Ensembl ENSG00000106128 ENSMUSG00000004654 UniProt Q02643 P32082 RefSeq (mRNA) NM_000823 NM_001009824 NM_001003685 RefSeq (protein) NP_000814 NP_001003685 Location (UCSC) Chr 7: 30.94 – 30.99 Mb Chr 6: 55.35 – 55.37 Mb PubMed search Wikidata View/Edit Human View/Edit Mouse The growth-hormone-releasing hormone receptor (GHRHR) is a G-protein-coupled receptor that binds growth hormone ...
Radiation therapy is commonly used in prostate cancer treatment. It may be used instead of surgery or after surgery in early-stage prostate cancer (adjuvant radiotherapy). Radiation treatments also can be combined with hormonal therapy for intermediate risk disease, when surgery or radiation therapy alone is less likely to cure the cancer.
Ads
related to: ghrhr receptor therapy for prostate cancer